World Health Organization Issues Warning Over Critical Shortage of Weight-Loss Injections
Fewer than one in 10 individuals eligible to benefit from GLP-1 drugs including Wegovy have access to them, warns the WHO as it releases its initial recommendations on the medications.
Given in excess of 1,000,000,000 people worldwide now obese, it is urging broader and more equitable availability to this class of drugs.
According to projections, more than two billion could be living with obesity by 2030 unless action is taken.
"The new guidelines affirms that obesity is a chronic disease that can be managed with thorough and lifelong care," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are major obstacles to broad access to the treatments that can assist patients in reducing significant weight, says the organization.
Skinny Jab Scarcity
Despite the present most optimistic case, the production of such drugs would only suffice for about 100 million people – less than 10% of the global need, as stated by the WHO.
The guideline encourages countries and companies to increase availability, via strategies such as voluntary licensing.
A patent on semaglutide – the core ingredient of a leading brand – is set to lapse in multiple countries in 2026.
The Way Weight-Loss Injections Operate
GLP-1 drugs imitate a body's own hormone to delay gastric emptying, reduce hunger and enhance the sense of being full so individuals consume fewer calories.
Individuals commonly see weight reduction in the initial weeks of starting on the once-weekly jabs.
Research suggests people may see weight return after a year of halting the drug, when their usual appetite come back.
Being carrying excess weight raises your risk for developing diseases, like diabetes, heart disease, brain attack, and some malignancies.
Excess weight concerns individuals in countries worldwide and was associated with over three and a half million fatalities worldwide in 2024, according to the WHO.
